Market Overview:
The global P2X purinoceptor 3 market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of chronic diseases, rising geriatric population, and growing demand for novel therapies. Based on type, the global P2X purinoceptor 3 market is segmented into OSX-300, ASN-009, BLU-5937, and others. Based on application, the global P2X purinoceptor 3 market is segmented into abdominal pain, endometriosis,, idiopathic pulmonary fibrosis (IPF), insomnia,, interstitial cystitis (IC), and others. Geographically speaking North America dominates this market followed by Europe while Asia Pacific is projected to grow at highest CAGR during forecast period owing to increase in awareness about benefits associated with use of these drugs among people coupled with rising healthcare expenditure in this region.
Product Definition:
P2X purinoceptor 3 is a receptor protein that helps mediate the actions of adenosine triphosphate (ATP) on cells. It is involved in many cellular activities, including cell proliferation, migration, and differentiation. P2X purinoceptor 3 may also play a role in tumorigenesis and metastasis.
OSX-300:
OSX-300 is a new name in the P2X purinoceptor family. OSX-300 was initially identified as an orphan receptor by its ability to mediate the inhibitory effects of various ligands including siltuximab, everolimus, and OSM-19/ASO [1]. The presence of multiple clinical trials investigating OSM-19/ASO for cancer treatment led to its identification as a potential drug target.
ASN-009:
ASN-009 is a selective purinergic receptor modulator (SPRM) that acts as an allosteric site-specific drug. It has been developed by Cipla, Inc. and is currently in phase II clinical trials for the treatment of hereditary angioedema (HAE).
Application Insights:
The application segment includes abdominal pain, endometriosis, idiopathic pulmonary fibrosis, insomnia and others. Endometriosis is estimated to be the fastest growing application segment over the forecast period owing to increasing awareness about pelvic pain and infertility. According to a study conducted by World Health Organization (WHO), in 2017 around 1.5 million women are diagnosed with endometriosis globally every year and this number is expected to increase by around 50% by 2030 globally.
P2X purinoceptor 3 has been found helpful in treating various other diseases such as interstitial lung disease (ILD), acute respiratory distress syndrome (ARDS) among others due to its ability of causing bronchodilation which helps in improving lung function along with other symptoms such as cough suppression and breathlessness improvement among adults suffering from ILD or ARDS respectively.
Regional Analysis:
North America dominated the global P2X purinoceptor market in 2017. This can be attributed to the presence of key players, high adoption rate of novel treatment options and increasing healthcare expenditure in this region. In addition, growing number of FDA approved drug candidates for chronic diseases is expected to drive regional growth over the forecast period. Asia Pacific is expected to witness lucrative CAGR during the forecast period due to rising incidence rates for interstitial lung disease (ILD), abdominal pain and IBS among others which are associated with hyper-reactivity of central nervous system (CNS) and gut motility respectively.
Growth Factors:
- Increasing prevalence of chronic pain conditions: The global prevalence of chronic pain is estimated to be around 20%, and this number is projected to grow in the coming years due to the aging population and rising rates of lifestyle-related diseases. This will create a larger pool of patients with chronic pain who may benefit from P2X purinoceptor 3 therapies.
- Growing interest in novel analgesic therapies: There is a growing interest in novel analgesic therapies, such as those that target P2X purinoceptors, as traditional treatments for chronic pain have often been found to be inadequate or ineffective. This could lead to increased adoption of P2X purinoceptor 3-targeted therapies in the future.
- Advances in understanding the role of P2X purinoceptors in chronic pain: There has been significant progress made recently in understanding the role that P2X purinoceptors play in mediating various aspects of chronic pain, including inflammation and nerve damage. This knowledge will help guide development efforts for new therapeutics targeting these receptors and may increase their commercial potential.
- Growing investment into analgesic drug development: The pharmaceutical industry has been investing significantly into developing new drugs for treating various forms of chronic pain, including those targeting P2X purinoceptors like P2X Purinoceptor 3 market . This indicates that there is high potential for successful commercialization efforts for products that can modulate these receptors effectively.
Scope Of The Report
Report Attributes
Report Details
Report Title
P2X Purinoceptor 3 Market Research Report
By Type
OSX-300, ASN-009, BLU-5937, Others
By Application
Abdominal Pain, Endometriosis, Idiopathic Pulmonary Fibrosis, Insomnia, Interstitial, Others
By Companies
Asana BioSciences LLC, Bayer AG, BELLUS Health Inc, Integral Molecular Inc, Merck & Co Inc, Neurim Pharmaceuticals Ltd, Pfizer Inc, Asana BioSciences LLC
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
151
Number of Tables & Figures
106
Customization Available
Yes, the report can be customized as per your need.
Global P2X Purinoceptor 3 Market Report Segments:
The global P2X Purinoceptor 3 market is segmented on the basis of:
Types
OSX-300, ASN-009, BLU-5937, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Abdominal Pain, Endometriosis, Idiopathic Pulmonary Fibrosis, Insomnia, Interstitial, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Asana BioSciences LLC
- Bayer AG
- BELLUS Health Inc
- Integral Molecular Inc
- Merck & Co Inc
- Neurim Pharmaceuticals Ltd
- Pfizer Inc
- Asana BioSciences LLC
Highlights of The P2X Purinoceptor 3 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- OSX-300
- ASN-009
- BLU-5937
- Others
- By Application:
- Abdominal Pain
- Endometriosis
- Idiopathic Pulmonary Fibrosis
- Insomnia
- Interstitial
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the P2X Purinoceptor 3 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
P2X Purinoceptor 3 is a receptor that responds to the purinergic signaling molecule, purin. This receptor is found in cells throughout the body and plays an important role in controlling inflammation and pain.
Some of the key players operating in the p2x purinoceptor 3 market are Asana BioSciences LLC, Bayer AG, BELLUS Health Inc, Integral Molecular Inc, Merck & Co Inc, Neurim Pharmaceuticals Ltd, Pfizer Inc, Asana BioSciences LLC.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 P2X Purinoceptor 3 Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 P2X Purinoceptor 3 Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 P2X Purinoceptor 3 Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the P2X Purinoceptor 3 Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global P2X Purinoceptor 3 Market Size & Forecast, 2020-2028
4.5.1 P2X Purinoceptor 3 Market Size and Y-o-Y Growth
4.5.2 P2X Purinoceptor 3 Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 OSX-300
5.2.2 ASN-009
5.2.3 BLU-5937
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Abdominal Pain
6.2.2 Endometriosis
6.2.3 Idiopathic Pulmonary Fibrosis
6.2.4 Insomnia
6.2.5 Interstitial
6.2.6 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global P2X Purinoceptor 3 Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 P2X Purinoceptor 3 Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 OSX-300
9.6.2 ASN-009
9.6.3 BLU-5937
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Abdominal Pain
9.10.2 Endometriosis
9.10.3 Idiopathic Pulmonary Fibrosis
9.10.4 Insomnia
9.10.5 Interstitial
9.10.6 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 OSX-300
10.6.2 ASN-009
10.6.3 BLU-5937
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Abdominal Pain
10.10.2 Endometriosis
10.10.3 Idiopathic Pulmonary Fibrosis
10.10.4 Insomnia
10.10.5 Interstitial
10.10.6 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 OSX-300
11.6.2 ASN-009
11.6.3 BLU-5937
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Abdominal Pain
11.10.2 Endometriosis
11.10.3 Idiopathic Pulmonary Fibrosis
11.10.4 Insomnia
11.10.5 Interstitial
11.10.6 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 OSX-300
12.6.2 ASN-009
12.6.3 BLU-5937
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Abdominal Pain
12.10.2 Endometriosis
12.10.3 Idiopathic Pulmonary Fibrosis
12.10.4 Insomnia
12.10.5 Interstitial
12.10.6 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 OSX-300
13.6.2 ASN-009
13.6.3 BLU-5937
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Abdominal Pain
13.10.2 Endometriosis
13.10.3 Idiopathic Pulmonary Fibrosis
13.10.4 Insomnia
13.10.5 Interstitial
13.10.6 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 P2X Purinoceptor 3 Market: Competitive Dashboard
14.2 Global P2X Purinoceptor 3 Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Asana BioSciences LLC
14.3.2 Bayer AG
14.3.3 BELLUS Health Inc
14.3.4 Integral Molecular Inc
14.3.5 Merck & Co Inc
14.3.6 Neurim Pharmaceuticals Ltd
14.3.7 Pfizer Inc
14.3.8 Asana BioSciences LLC
